Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03849469
Title A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Xencor, Inc.

endometrial carcinoma


gastroesophageal junction adenocarcinoma

head and neck squamous cell carcinoma

triple-receptor negative breast cancer

transitional cell carcinoma

hepatocellular carcinoma

cervix carcinoma

nasopharynx carcinoma

colorectal carcinoma

pancreatic carcinoma

lung non-small cell carcinoma

gastric adenocarcinoma

renal cell carcinoma

lung small cell carcinoma


Pembrolizumab + XmAb22841


Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.